Novice

6. 10. 2017

Discover our new corporate video

 

4. 10. 2017

Servier opts for Saclay as its future Research Centre

 

25. 9. 2017

Subscription to the second scientific days conference organized by L’Institut Servier

 

19. 9. 2017

Servier and Geneuro to present six-month results from CHANGE-MS phase 2b study in multiple sclerosis at MSParis2017

 

15. 9. 2017

Servier is actively involved in World Lymphoma Awareness Day

 

7. 9. 2017

Servier awards its Research Fellowship to a young European researcher in cardiology

 

6. 9. 2017

A campaign in Poland to raise awareness of colorectal cancer

 

5. 9. 2017

Servier and Institut Curie extend duration and scope of partnership in fight against cancer

 

30. 8. 2017

Servier’s presence at the annual congress of the European Society of Cardiology (ESC)

 

28. 8. 2017

Five Chinese researchers receive awards jointly from Servier and the Chinese Pharmaceutical Association

 

28. 8. 2017

Servier and GeNeuro Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis

 

24. 8. 2017

WeHealth by Servier, Servier’s e-health department, teams up with CardioRenal to provide better support to heart failure patients

 

3. 8. 2017

Servier Tianjin ranked in the top 100 businesses of TEDA in China

 

31. 7. 2017

Servier licenses GLPG1972 in osteoarthritis from Galapagos

 

29. 6. 2017

Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.

 

27. 6. 2017

Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness

 

31. 5. 2017

Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases

 

3. 5. 2017

Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics

 

26. 4. 2017

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

 

25. 4. 2017

Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®

 

28. 3. 2017

Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market

 

27. 3. 2017

Dr Claude Bertrand, General Director of Research and Development at Servier

 

16. 3. 2017

Servier Research Fellowship awarded by the International Union of Phlebology - Union Internationale de Phlébologie / 2017-2019 submission

 

14. 3. 2017

Servier and Neurochlore join forces to treat autism in children

 

14. 3. 2017

Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017

 

9. 3. 2017

Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

 

6. 3. 2017

Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.

 

3. 3. 2017

Servier successfully issues euro private placement

 

1. 3. 2017

Bolniki z napredovanim metastatskim kolorektalnim rakom (mKRR) imajo v Sloveniji na voljo novo zdravilo

 

14. 2. 2017

Servier and GAIA extend their partnership to provide patients around the world with deprexis®, an internet-based cognitive behavioral therapy for depression

 

7. 2. 2017 

Servier announces an increase in turnover for 2015-2016

 

18. 1. 2017

Servier appoints MaSTherCell for the development of its CAR-T cell therapy manufacturing platform 

 

5. 1. 2017

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance

 

28. 12. 2016

OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

 

7. 12. 2016

GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis

 

8. 11. 2016

Servier signs agreement with non-profit association La Chaîne de l'Espoir and announces creation of the Mécénat Servier endowment fund

 

20. 10. 2016

New compound shows promise in treating multiple human cancers

1. 9. 2016

Amgen and Servier extend Omecamtiv Mecarbil collaboration in Chronic Heart Failure
 

27. 7. 2016

Servier invests in bioproduction in France

11. 7. 2016

Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody

 

27. 4. 2016

Evropskim bolnikom z napredovalim metastatskim kolorektalnim rakom je zdaj na voljo novo zdravilo LONSURF® (trifluridin/tipiracil), ki je pridobilo dovoljenje za promet v Evropi

 

22. 4. 2016

ISHR-ES – Servier Research Fellowship 2016 awarded to Dr Hector Cabrera-Fuentes

 

6. 4. 2016

40th year of operations in Brazil

 

1. 4. 2016

Withdrawal of fusafungine-containing medicines from the market

 

26. 2. 2016

Servier je pridobil pozitivno mnenje odbora CHMP za zdravilo Lonsurf® (trifluridin/tipiracil) za zdravljenje neodzivnega metastatskega kolorektalnega raka 

 

12. 2. 2016
EMA Benefit/Risk Revision of Fusafungine-Containing Medicines

 

11.1.2016

Spectrum Pharmaceuticals Signs a Strategic Partnership with Servier Canada

 

18. 12. 2015
GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment

 

7. 12. 2015
Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates targeting apoptosis

 

20. 11. 2015
Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier

 

19. 11. 2015
Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

 

14. 10. 2015
Professor Félix Rey, winner of the 2015 Pasteur-Weizmann / Servier Award, for his work in the field of emerging pathogenic viruses

 

7. 10. 2015
ISHR-ES – Servier Research Fellowship 2016 / Deadline for applications: December 15, 2015

 

7. 10. 2015
Horizon Discovery Group plc In-licenses Oncology Programme from Servier and Enters Option Agreement

 

5. 10. 2015
Crossbeta and Servier announce strategic oligomer-based research collaboration in neurological diseases involving misfolded proteins

 

5. 10. 2015
Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners.

 

24. 09. 2015
Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial

 

01. 04. 2015
An ESCEO-IOF/Servier Achievement Award: the 2015 Pierre Delmas Prize winner is Professor Jean-Yves Reginster

 

02. 11. 2014
G. B. Morgagni Prizes 2014 Winners

 

06. 08. 2015
ISHR-ES – Servier Research Fellowship 2015 awarded to Dr Pietro Ameri 

 

06. 08. 2015
SERVIER Award in Microcirculation: the winners are Claudia Nussbaum and Sarah Bannenberg

 

06. 08. 2015
SERVIER Research Grant in Hypertension: the winner is Dr Sébastien Foulquier

 

09. 07. 2014
Cellectis Reaches Milestone in Servier Collaboration

 

17. 06. 2015
VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER

 

15. 06. 2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe

 

04. 06. 2015
2015-2017 Winner of the UIP/Servier Fellowship

 

16. 04. 2015
FDA approves ivabradine for patients with chronic heart failure

 

01. 04. 2015
Servier Initiates Phase 2 Study of Gevokizumab in Patients with Diabetic Nephropathy

 

26. 01. 2015
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors

 

26. 01. 2015
FDA approval of antihypertensive Prestalia® A codevelopment by Symplmed and Servier

 

 

  

Več informacij: www.servier.com

Servier Communication Department

Tel: +33 1 5572 6037

Email: presse@servier.fr

 

arhiv novic